获批临床！智飞生物冻干水痘灭活疫苗迎重大进展 持续以技术创新构建产品壁垒

Core Viewpoint - Zhifei Biological has received approval from the National Medical Products Administration for clinical trials of its self-developed lyophilized varicella inactivated vaccine, aimed at preventing varicella caused by varicella-zoster virus infection [1][5]. Group 1: Vaccine Development - The varicella vaccine is designed to prevent varicella, an acute infectious disease caused by the varicella-zoster virus, which poses significant health risks, especially to children and immunocompromised individuals [5]. - The vaccine is considered the most economical and effective method for preventing varicella [5]. Group 2: Company Positioning - Zhifei Biological has a strong presence in vaccine research and development, supported by rigorous scientific approaches, substantial technical accumulation, and continuous R&D investment [5]. - The approval of the varicella vaccine for clinical trials reflects the company's commitment to addressing public health needs and fulfilling social responsibilities [5]. - Successful progress in this project is expected to enhance the company's vaccine portfolio, improve product layout, and strengthen its market position [5].